Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer

Opinion
Video

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      • For patients who no longer benefit from prior endocrine therapy, what is your current approach to treatment sequencing in HR+/HER2-low metastatic breast cancer?
      • What are some unmet needs and ongoing challenges in patients with HR+/HER2-low breast cancer?
      Related Content